Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Better For You Wellness, Inc.BFYW · Entity 91229 | Director | July 18, 2023 | March 06, 2024 |
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | February 05, 2026 | February 06, 2026 |
| Sorrento Therapeutics, Inc.SRNE · Entity 109201 | Director | September 15, 2017 | September 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Better For You Wellness, Inc.
Report date July 18, 2023 · Filed March 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,949,018 |
Ending reported balance
After 2024-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-18 · Grant · Acquired 5,270,271 · Balance 5,874,018 F1: 5,874,018 shares were issued as a part of a Loan Conversion Agreement of July 18, 2023, which was the subject of an 8-K the same day. The Form 4 for this conversion was inadvertently un-filed due to a clerical error. Row 2 · 2024-02-28 · Grant · Acquired 75,000 · Balance 5,949,018 F2: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters) and extended an additional 8 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: 5,874,018 shares were issued as a part of a Loan Conversion Agreement of July 18, 2023, which was the subject of an 8-K the same day. The Form 4 for this conversion was inadvertently un-filed due to a clerical error.
F2: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters) and extended an additional 8 quarters.
Phio Pharmaceuticals Corp.
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 37,800 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 23,800 · Balance 37,800 F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2: Includes shares of common stock underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
F2: Includes shares of common stock underlying unvested restricted stock units.
Sorrento Therapeutics, Inc.
Report date September 15, 2017 · Filed September 18, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-09-15 | Direct | 35,000 |
Reported balance
After 2017-09-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-09-15 · Grant · Acquired 35,000 · Balance 35,000 F1: This amended report on Form 4 is being filed to amend the Form 4 filed by the reporting person on September 15, 2017 to correct the exercise price, which was inadvertently reported as $1.75. F2: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This amended report on Form 4 is being filed to amend the Form 4 filed by the reporting person on September 15, 2017 to correct the exercise price, which was inadvertently reported as $1.75.
F2: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBANY MOLECULAR RESEARCH INC
Report date August 31, 2017 · Filed September 05, 2017
Section 16 reporting ended · disclosed 2017-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 1
1 source rowRow 1 · 2017-08-31 · Disposition to issuer · Disposed 6,838 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2027-02-08 | Direct | Not disclosed |
Reported balance
After 2017-08-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-08-31 · Disposition to issuer · Disposed 9,358 · Balance Not disclosed F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 6, 2026 12:59 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 23,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-000809 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,800 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 12:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-25-006961 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 28, 2024 Filed Mar 6, 2024 21:23 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001575872-24-000208 · ownership.xml · nonDerivative · entry 2 Deming David H · CIK 0001641063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,949,018 F2 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters) and extended an additional 8 quarters. Read SEC document |
| July 18, 2023 Filed Mar 6, 2024 21:23 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 5,270,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001575872-24-000208 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,874,018 F1 · shares: 5,874,018 shares were issued as a part of a Loan Conversion Agreement of July 18, 2023, which was the subject of an 8-K the same day. The Form 4 for this conversion was inadvertently un-filed due to a clerical error. Read SEC document |
| June 02, 2023 Filed Jun 12, 2023 21:12 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001575872-23-000933 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 603,747 F1 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 14:44 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-025084 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 578,747 F1 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). Read SEC document |
| December 01, 2022 Filed Mar 28, 2023 17:19 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-023555 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,747 F1 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 19:14 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-053142 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,747 F1 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 12:45 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-038996 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,747 F1 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 20:35 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-019623 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,747 F1 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). F1 · price: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:24 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-000658 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,747 F1 · shares: 25,000 shares of Common Stock are granted every quarter starting on September 30, 2021, under certain conditions (200,000 shares of Common Stock in total over a period of eight quarters). Read SEC document |
| December 14, 2021 Filed Dec 20, 2021 22:01 UTC | Better For You Wellness, Inc. BFYW · Entity 91229 | GrantCommon Stock | 403,747 | $0.12 | $49,983.88 |
DisclosureSEC source: 0001213900-21-066391 · ownership.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,747 Read SEC document |
| September 15, 2017 Filed Sep 15, 2017 21:45 UTC | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001144204-17-048360 · v475326_4.xml · derivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-09-15 F1 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 06:18 UTC Amendment | Sorrento Therapeutics, Inc. SRNE · Entity 109201 | GrantStock Options · Derivative | 35,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001144204-17-048376 · v475338_4a.xml · derivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-09-15 F1 · derivative.exercise_price: This amended report on Form 4 is being filed to amend the Form 4 filed by the reporting person on September 15, 2017 to correct the exercise price, which was inadvertently reported as $1.75. F2 · derivative.exercise_date: 1/12 of the original number of shares subject to this option shall vest and become exercisable following each one month of service thereafter, subject to the reporting person's continued service on the issuer's board of directors on each such date. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:28 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 9,358 | $3.34 Strike: $18.41 | $31,255.72 |
DisclosureSEC source: 0001638599-17-000874 · doc4_4883.xml · derivative · entry 2 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 9,358 shares Expires 2027-02-08 F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:28 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerCommon Stock | 6,838 | $21.75 | $148,726.50 |
DisclosureSEC source: 0001638599-17-000874 · doc4_4883.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantOption to Purchase Common Stock · Derivative | 9,358 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001638599-17-000187 · doc4_4545.xml · derivative · entry 2 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,358 Underlying: Common Stock · 9,358 shares Expires 2027-02-08 F1 · derivative.exercise_date: Option is exercisable as to 1/3rd of the shares annually on the anniversary date of the grant for each of the next three years. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 3,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000187 · doc4_4545.xml · nonDerivative · entry 1 Deming David H · CIK 0001641063 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,838 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.